del Muro XG, et al. - Preclinical studies suggested that treatment with sorafenib plus cytotoxic agents could result in additive efficacy. In this current investigation, it was demonstrated that sorafenib plus ifosfamide, when given to patients with advanced soft tissue sarcoma resistant to anthracyclines, showed an acceptable safety profile as well as led to the achievement of a significant clinical benefit.